Oncology
Cancer cell

Building a Phase I oncology centre

The question is not whether an institution should ultimately develop Phase Ia capability. It is when the organisation is ready.

Market Access
NICE technology appraisals

Who delays NICE technology appraisals anyway?

Leela Barham looks at the speediness of NICE’s technology appraisals and ongoing efforts to hit the target of NICE publishing final guidance within 90 days of marketing authorisation.

Digital
open-source data

Transforming clinical trials with open-source tech

Clinical trials historically struggled with several key inefficiencies, many of which became painfully apparent during the COVID-19 pandemic, such as the traditional paper-based, manual rev

Sales & Marketing

Digital

Market Access

Market Access
Mumbai, India

What India can learn from Kinvard Bio

India needs its own version of pull, designed for an Indian payer mix, an Indian procurement structure, and an Indian distributor network.

Editor's Picks

  1. Revolution's ASCO showstopper gets FDA greenlight
  2. Anthropic AI tool conducts physical scientific experiments
  3. UK MHRA authorises orforglipron private prescription
  4. Roche’s Genentech strikes $2.3bn deal for Hanmi obesity drug HM17321
  5. Sword Health buys Headspace in $200m to $300m deal

Newsletters and Deep Dive
digital magazine

Oncology

Oncology
Cancer cell

Building a Phase I oncology centre

The question is not whether an institution should ultimately develop Phase Ia capability. It is when the organisation is ready.

more

Patients

more

R&D

more